Seema A. Bhat

2.6k total citations · 1 hit paper
69 papers, 1.4k citations indexed

About

Seema A. Bhat is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Seema A. Bhat has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Genetics, 29 papers in Pathology and Forensic Medicine and 17 papers in Immunology. Recurrent topics in Seema A. Bhat's work include Chronic Lymphocytic Leukemia Research (61 papers), Lymphoma Diagnosis and Treatment (29 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). Seema A. Bhat is often cited by papers focused on Chronic Lymphocytic Leukemia Research (61 papers), Lymphoma Diagnosis and Treatment (29 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). Seema A. Bhat collaborates with scholars based in United States, United Kingdom and Poland. Seema A. Bhat's co-authors include Liam Murray, B. T. Johnston, Foad Yousef, Helen G. Coleman, Damian McManus, Anna Gavin, Jennifer A. Woyach, John C. Byrd, Kerry A. Rogers and Farrukh T. Awan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Seema A. Bhat

60 papers receiving 1.4k citations

Hit Papers

Risk of Malignant Progression in Barrett's Esophagus Pati... 2011 2026 2016 2021 2011 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Risk of Malignant Progression in Barrett's Esophagus Patients: Results from a Large Population-Based Study
    2011 498 citations Seema A. Bhat et al. profile →

Peers

Seema A. Bhat
Christina Balser Germany
Lluı́s Colomo Spain
Harish K. Gagneja United States
K Thorling Denmark
Heidi D. Finnes United States
Mirella Marino Italy
Marlene Troch Austria
M. Fickers Netherlands
Jean‐Marc Zini France
Paula Cramer Germany
Christina Balser Germany
Seema A. Bhat
Citations per year, relative to Seema A. Bhat Seema A. Bhat (= 1×) peers Christina Balser

Countries citing papers authored by Seema A. Bhat

Since Specialization
Citations

This map shows the geographic impact of Seema A. Bhat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seema A. Bhat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seema A. Bhat more than expected).

Fields of papers citing papers by Seema A. Bhat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seema A. Bhat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seema A. Bhat. The network helps show where Seema A. Bhat may publish in the future.

Co-authorship network of co-authors of Seema A. Bhat

This figure shows the co-authorship network connecting the top 25 collaborators of Seema A. Bhat. A scholar is included among the top collaborators of Seema A. Bhat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seema A. Bhat. Seema A. Bhat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cohen, Alex S., et al.. (2025). A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials. Biological Psychiatry.
2.
Zhao, Qiuhong, Andrew Stiff, Seema A. Bhat, et al.. (2024). Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia. SHILAP Revista de lepidopterología. 5(5). 1005–1009.
3.
Ruz, Patrick, Adam S. Kittai, Kerry A. Rogers, et al.. (2024). Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. Leukemia. 38(10). 2141–2149. 5 indexed citations
4.
Omer, Zulfa, Jennifer A. Woyach, Seema A. Bhat, et al.. (2024). Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation. Blood. 144(Supplement 1). 1875–1875.
5.
Woyach, Jennifer A., Deborah M. Stephens, Ian W. Flinn, et al.. (2023). First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma. Cancer Discovery. 14(1). 66–75. 29 indexed citations
6.
Kittai, Adam S., Seema A. Bhat, Michael R. Grever, et al.. (2023). Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization. Blood Advances. 7(23). 7239–7242. 4 indexed citations
7.
Huang, Ying, Mirela Anghelina, Seema A. Bhat, et al.. (2023). Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2. SHILAP Revista de lepidopterología. 4(4). 1200–1202. 1 indexed citations
8.
Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations
9.
Bhat, Seema A., Marilly Palettas, Tracy Wiczer, et al.. (2022). Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood. 140(20). 2142–2145. 46 indexed citations
10.
Anghelina, Mirela, Michelle J. Naughton, Qiuhong Zhao, et al.. (2022). Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia. Leukemia Research. 120. 106919–106919. 1 indexed citations
11.
Zhao, Qiuhong, Tracy Wiczer, Marilly Palettas, et al.. (2022). Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. Journal of Hematology & Oncology. 15(1). 92–92. 21 indexed citations
12.
Kittai, Adam S., Cecelia Miller, Ying Huang, et al.. (2021). The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 138(23). 2372–2382. 31 indexed citations
13.
Wiczer, Tracy, Marilly Palettas, Seema A. Bhat, et al.. (2021). Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy. Blood. 138(Supplement 1). 3729–3729. 4 indexed citations
14.
Miller, Cecelia, Ying Huang, Amy S. Ruppert, et al.. (2021). Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia. 35(11). 3287–3290.
15.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discovery. 10(3). 394–405. 57 indexed citations
16.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 16–18. 12 indexed citations
17.
Bond, David A., Ying Huang, James L. Fisher, et al.. (2020). Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 34(12). 3197–3205. 33 indexed citations
18.
Woyach, Jennifer A., Ying Huang, Kerry A. Rogers, et al.. (2019). Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations. Blood. 134(Supplement_1). 504–504. 76 indexed citations
19.
20.
Pokuri, Venkata K., et al.. (2015). Interdigitating Dendritic Cell Sarcoma. Journal of the National Comprehensive Cancer Network. 13(2). 128–132. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina Balser Breakdown of academic impact, for papers by Lluı́s Colomo Breakdown of academic impact, for papers by Harish K. Gagneja Breakdown of academic impact, for papers by K Thorling Breakdown of academic impact, for papers by Heidi D. Finnes Breakdown of academic impact, for papers by Mirella Marino Breakdown of academic impact, for papers by Marlene Troch Breakdown of academic impact, for papers by M. Fickers Breakdown of academic impact, for papers by Jean‐Marc Zini Breakdown of academic impact, for papers by Paula Cramer
Rankless by CCL
2026